On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Howard D. Homesley

ResearcherPublications, citations & collaboration network

Howard D. Homesley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Howard D. Homesley have?

ScholarIQindexed works

Howard D. Homesley has 207 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Howard D. Homesley have?

ScholarIQcitation count

Howard D. Homesley has 16,127 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Howard D. Homesley?

ScholarIQh-index

Howard D. Homesley has an h-index of 53 in OpenAlex.

What is the i10-index of Howard D. Homesley?

ScholarIQi10-index

Howard D. Homesley has an i10-index of 126 in OpenAlex.

What is the OpenAlex record for Howard D. Homesley?

ScholarIQopenalex

The OpenAlex for Howard D. Homesley is on the source record.

What are the most-cited papers on Howard D. Homesley?

ScholarIQmost cited works
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang
New England Journal of Medicine. 20112,398 CitationsOPEN ACCESS
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Barbara M. Norquist, Elizabeth M. Swisher, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Helen Huang, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Sharon X. Liang, Chenglin Ye, Carlos Bais, Leslie M. Randall, John K. Chan, J. Stuart Ferriss, Robert L. Coleman, Carol Aghajanian, Thomas J. Herzog, Philip J. DiSaia, Larry J. Copeland, Robert S. Mannel, Michael J. Birrer, Bradley J. Monk
Journal of Clinical Oncology. 2019488 CitationsOPEN ACCESS
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
Martee L. Hensley, John A. Blessing, Koen DeGeest, Ovadia Abulafia, Peter G. Rose, Howard D. Homesley
Gynecologic Oncology. 2008365 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account